BDR Pharma to acquire stake in Acme Formulation's oral solid business

BDR Pharma has announced the acquisition of a controlling stake in the oral solid formulation business of Acme Formulation and its subsidiaries. Under this transaction, stakes will be purchased from existing shareholders, with alternative investment firm PAG playing a key role. According to a report by 'The Hindu', the total value of this deal has been set at $250 million.

According to BDR Pharma, the primary objective behind this acquisition is to add complementary capabilities in thyroid products, female sex hormone products, and general pharmaceutical products. This strategic decision aligns with the company's growth priorities in the oncology, critical care, and women's health sectors. Additionally, this deal will create new opportunities to expand the company's product offerings in international markets.

Commenting on this, Dharmesh Shah, Chairman and Managing Director of BDR Pharma, stated that Acme will strengthen the company's CDMO platform and add diverse capabilities to it. He further added that this acquisition is part of the company's larger growth roadmap, through which they are continuously expanding their global presence.

As part of this deal, after selling the controlling stake in the oral solid business, PAG and Viral Shah will retain full ownership of 'Immacule'. Immacule is a contract manufacturing company focusing on sterile injectables. The company has recently commissioned a new facility with a capacity of 20 crore units, providing operations across various dosage forms and therapeutic areas.

Expressing confidence in this partnership, Acme founder and Managing Director of Immacule, Viral Shah, said that BDR Pharma's strength in manufacturing new and complex medicines will bring more innovative products to Acme's CMO and CDMO customers. This collaboration will benefit customers across various geographical regions.

BDR Pharma is a leading pharmaceutical company primarily engaged in the production and research of complex medicines such as oncology and critical care. The company has long been making various strategic investments and acquisitions to increase its manufacturing capacity and range of medicines globally, with the aim of providing affordable and effective healthcare services to patients.